Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 51, Issue 9, Pages 1418-1430Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.077164
Keywords
PET; dementia; neurodegenerative disorders; functional activity; neurotransmitter pathology
Funding
- Swedish Research Council [05817]
- Stohne's Foundation
- Foundation of Old Servants
- KI Foundations
- Alzheimer Foundation in Sweden
- Demensfonden
- Brain Foundation
- Swedish Brain Power
- Knut and Alice Wallenberg Foundation
- EC [LSHB-CT-2005-512146]
Ask authors/readers for more resources
Dementia is a highly prevalent problem causing considerable disability and mortality and exacting great costs to individuals, their families, and society. The 4 most common neurodegenerative disorders that cause dementia-Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, and dementia in Parkinson disease-have different underlying etiologies and pathogenetic mechanisms. There is a great need for early diagnostic markers; functional brain imaging may therefore assist in the detection and differential diagnosis of dementia due to neurodegenerative diseases. Functional imaging such as PET allows in vivo imaging of functional brain activity indicating cerebral blood flow and cerebral glucose metabolism, and PET allows imaging of neurotransmitter activity, including that of the cholinergic, dopaminergic, and serotonergic systems. New PET neuroimaging tracers are being developed for detecting pathologic parameters such as amyloid plaque and microglial activity. The development of molecular imaging is important for early diagnosis of dementia, selection of patients for therapies, and evaluation of therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available